mechanical hemolytic anemia (MHA) is a serious complication after heart valve surgery. If improperly treated, it can cause multiple organ failure and lead to death. The mechanism of its generation has been reported in the literature[1,2,3]。 In the past, the incidence of MHA was high, but with the improvement of valve fabrication technology and histocompatibility of materials used, the incidence of MHA has been significantly reduced. MHA due to technical problems and histocompatibility is rare in clinical practice when the heart valve functions normally, but it is not uncommon to occur in the case of mitral valvuloplasty (MVP), residual regurgitation after valvuloplasty, or paravalvular leakage of prosthetic valves, etc. It is one of the important reasons leading to the need for reoperation after heart valve replacement or plasty[2,4,5,6]。 At present, MHA after heart valve surgery is rare, and the experience in diagnosing and managing mechanical MHA after surgery is relatively insufficient, which easily leads to misdiagnosis and mistreatment. The incidence, harm, diagnosis and treatment of MHA after MVP are discussed, and the treatment experience is summarized in order to reduce the disability rate and mortality rate.